The addition of the dendritic cell-based immunotherapy DCVAC/OvCA to standard carboplatin and gemcitabine led to a significant improvement in overall survival in patients with relapsed, platinum-sensitive, epithelial ovarian cancer.
FLT3 inhibition continues to be explored as a therapeutic option for patients with FLT3-mutant acute myeloid leukemia, with quizartinib at the forefront following intriguing results of the phase III QuANTUM-R trial.
Dae Won Kim, MD, highlights recent advances in the neoadjuvant and adjuvant settings for patients with localized pancreatic cancer.
Immune-based approaches have revolutionized the treatment of acute lymphoblastic lymphoma, especially for patients unable to tolerate multiagent chemotherapy. Now, investigators are looking forward to seeing these agents move into frontline settings, perhaps leading to chemotherapy-free approaches.
Richard Kim, MD, discusses the therapeutic landscape of advanced hepatocellular carcinoma in light of recent findings and highlighted anticipated research in the field.
Chemokine receptor type 2, a major recruiter of circulating monocytes that subsequently develop into a protumoral type of macrophage within the tumor microenvironment, has emerged as a promising therapeutic target.
The FDA has granted an approval to the combination of atezolizumab with carboplatin and etoposide for the frontline treatment of patients with extensive-stage small cell lung cancer.
Treatment with neratinib led to a clinical benefit rate of 54.5% in patients with HER2-mutant cervical cancer.
Atezolizumab (Tecentriq) demonstrated consistent safety and efficacy with prior studies of the PD-L1 inhibitor in patients with locally advanced or metastatic urothelial carcinoma, including clinically relevant subgroups reflective of real-world clinical practice.
Brian I. Rini, MD, discusses the next steps with tivozanib (Fotivda) and immunotherapy/TKI combinations in patients with metastatic renal cell carcinoma.